VIEW AN ABSTRACT

VALIDATION OF THE CARDIOMETABOLIC-BASED CHRONIC DISEASE (CMBCD) MODEL IN U.S. ADULTS. Topic: Primary prevention
Type: Presentation - doctors , Number in the programme: 52


Gonzalez Rivas J.¹, Pavlovska I.², Nieto-Martinez R.³, Infante-Garcia M.², Hlinomaz O.⁴, Medina-Inojosa J.⁵, Broz J.⁶, Maranhao Neto G.², Mechanick J.⁷ ¹ Kardiovize, International Clinical Research Center of St. Annes University Hospital in Brno, Brno, ² Kardiovize, International Clinical Research Centre (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic, Brno, ³ Global Healht, Department of Global Health and Population. Harvard TH Chan School of Public Health. Harvard University, Boston, Massachusetts, USA., Boston, United States, ⁴ Cardiology, International Clinical Research Centre (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic, Brno, ⁵ Cardiovascular Medicine, Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, MN,USA, Rochester, United States, ⁶ Internal Medicine, Charles University Second Faculty of Medicine, Department of Internal Medicine, Praha, Praha, Czech Republic, Praha, ⁷ Endocrinology, The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Heart, and 4 Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, United States
Background: The Cardiometabolic-Based Chronic Disease (CMBCD) model is a four-stage driver and complication-based chronic approach. It was designed as an actionable strategy, advocating for earlier intervention Aim: To validate the CMBCD model by examining risk for CVD and all-cause mortality Methods: Data from the National Health and Nutrition Examination Surveys (NHANES) of the US (1999-2012) was linked to mortality files until 2015. Adults aged 40-74 years were analyzed. The CMBCD model is divided into 4 stages: 1-risk, 2–predisease, 3–disease, and 4–complications. Kaplan-Meier survival curve estimates and Cox regression models were calculated. Results: 7261 subjects were included, mean age of 53.5 ± 0.18 years, followed by 8.1 years. There were 160 CVD and 811 all-cause deathly cases. The cumulative rates for CVD and all-cause mortalities rates were 2.5 and 12.9 per 1000 person-years, respectively. The cumulative CVD-mortality rates for each CMBCD stage were without risk/stage 1, 0.8; stage 2, 1.1; stage 3, 1.7; and stage 4, 6.3, per 1000 person-years (pConclusion: Subjects with complications presented a higher risk of mortality than those without it. These results highlight the relevance of early detection and intervention using a complication-based chronic approach.